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Objective. Diffuse alveolar hemorrhage (DAH) in lupus patients confers >50% mortality, and the cause is unknown. We undertook this study to examine the pathogenesis of DAH in C57BL/6 mice with pristane-induced lupus, a model of human lupus-associated DAH.
Methods. Clinical/pathologic and immunologic manifestations of DAH in pristane-induced lupus were compared with those of DAH in humans. Tissue distribution of pristane was examined by mass spectrometry. Cell types responsible for disease were determined by in vivo depletion using clodronate liposomes and antineutrophil monoclonal antibodies (anti-Ly-6G). The effect of complement depletion with cobra venom factor (CVF) was examined.
Results. After intraperitoneal injection, pristane migrated to the lung, causing cell death, small vessel vasculitis, and alveolar hemorrhage similar to that seen in DAH in humans. B cell-deficient mice were resistant to induction of DAH, but susceptibility was restored by infusing IgM. C3 2/2 and CD18 2/2 mice were also resistant, and DAH was prevented in wild-type mice by CVF. Induction of DAH was independent of Toll-like receptors, inflammasomes, and inducible nitric oxide. Mortality was increased in interleukin-10 (IL-10)-deficient mice, and pristane treatment decreased IL-10 receptor expression in monocytes and STAT-3 phosphorylation in lung macrophages. In vivo neutrophil depletion was not protective, while treatment with clodronate liposomes prevented DAH, which suggests that macrophage activation is central to DAH pathogenesis.
Conclusion. The pathogenesis of DAH involves opsonization of dead cells by natural IgM and complement followed by complement receptor-mediated lung inflammation. The disease is macrophage dependent, and IL-10 is protective. Complement inhibition and/or macrophage-targeted therapies may reduce mortality in lupus-associated DAH.
Although frequently unrecognized, lung disease occurs in half of patients with systemic lupus erythematosus (SLE). Manifestations include pleuritis, pulmonary hypertension, and interstitial lung disease (1) . Only ;3% of SLE patients develop diffuse alveolar hemorrhage (DAH), but it is a significant problem with .50% mortality (2, 3) . Clinical features include hemoptysis, falling hemoglobin levels, and a strong association with lupus nephritis (3, 4) . Pathologic examination reveals hemosiderin-laden macrophages, bland hemorrhage, and/or pulmonary capillaritis (3) . The pathogenesis remains unclear.
C57BL/6 (B6) mice with pristane-induced lupus develop DAH manifested by alveolar and perivascular inflammation (capillaritis, small vessel vasculitis), hemorrhage, endothelial injury, and infiltration of macrophages, neutrophils, lymphocytes, and eosinophils (5, 6) . Antineutrophil cytoplasmic antibodies (ANCAs) are absent (6) . Recruitment of macrophages and neutrophils precedes hemorrhage, starting 3 days after pristane injection and peaking at 2 weeks (7). DAH is independent of myeloid differentiation factor 88 (MyD88), Toll-like receptor 7 (TLR-7), Fcg receptor, Fas, and T cells, but immunoglobulin-deficient (mMT) mice (7) are resistant. The present studies were carried out to further define the pathogenesis of DAH in this model.
MATERIALS AND METHODS
Mice and pristane treatment. Mice were bred and maintained under specific pathogen-free conditions. ) mice were bred at the University of Florida. To induce lupus, 0.5 ml of pristane (Sigma-Aldrich) was administered intraperitoneally (IP). Controls were left untreated. Peritoneal exudate cells were collected by lavage. In some experiments, bronchoalveolar lavage (BAL) was performed. After mice were euthanized, a small incision was cut in the trachea and the alveolar spaces were lavaged with 1 ml of phosphate buffered saline (PBS). Cells collected by BAL were resuspended in RPMI 1640 plus 10% fetal bovine serum (FBS) and incubated at 37 C for 1 hour before treating with IL-10 (1 ng/ml). After a 15-minute incubation, the cells were fixed, permeabilized, surface stained with anti-CD11b antibodies, and stained intracellularly with anti-phospho-STAT-3 antibodies as described below. These studies were approved by the Institutional Animal Care and Use Committee.
Immunoglobulin infusion in mMT mice. Similar to IFN production in pristane-treated mice (8) , ischemiareperfusion injury in mice is mediated by the early classical complement cascade and natural IgM (9) . Human natural IgM is as effective as murine IgM at inducing ischemiareperfusion injury (10) . In light of these observations and in view of the relative ease of obtaining human IgM versus mouse IgM, the requirement for immunoglobulin in DAH was evaluated by administering purified human IgM (50 or 200 mg/ mouse; Sigma-Aldrich), murine IgG (200 mg/mouse; SigmaAldrich), or PBS intravenously (IV) to mMT mice 1 day before and 7 days after pristane treatment. DAH was assessed at 14 days.
Cobra venom factor (CVF) treatment. Mice were treated with 10 mg CVF (CompTech) IP 1 day before and 7 days after pristane treatment. C3 depletion was monitored by enzyme-linked immunosorbent assay using anti-C3 antibodies (Bioss). DAH was assessed at 14 days.
Lung pathology. Formalin-fixed, paraffin-embedded archived lung biopsy tissue from a 19-year-old woman with lupus nephritis who had developed massive hemoptysis and DAH was sectioned (4 mm) and stained with hematoxylin and eosin (H&E). Pristane-treated mice were euthanized at 14 days, and lungs were fixed in formalin. DAH was evaluated by gross inspection of excised lungs and confirmed by microscopy. Tissue sections were subjected to antigen retrieval and analyzed by TUNEL assay (ApopTag Peroxidase In Situ Apoptosis Detection Kit; Chemicon/Millipore). Neutrophil elastase was detected by immunohistochemistry with polyclonal anti-rabbit antielastase antibodies at 1:50 dilution for 60 minutes (Abcam) and quantified morphometrically. The expression area and staining intensity were quantified using MetaMorph Premier Image Analysis Software (Molecular Devices). Staining intensity (thresholded area) was expressed as a percentage of total examined lung cell area after subtracting noncellular space from total area.
Staining with oil red O was performed on 10-mm frozen sections of lung tissue from pristane-treated mice or untreated controls (11) . Tissue was counterstained with Mayer's hematoxylin and viewed under a microscope.
Pristane-induced in vitro cell death. Pristane or mineral oil (a hydrocarbon oil that does not cause lupus) was dissolved/emulsified in PBS containing 100 mg/ml bovine serum albumin (BSA). At saturation, the solution contained 37.2 mg/ ml of pristane. Mineral oil was mixed with PBS/BSA at the same concentration. BW5147 cells (murine thymoma; ATCC) and RAW 264.7 cells (murine macrophage; ATCC) were incubated for 24 hours at 8 3 10 5 /ml in RPMI 1640 containing 10% FBS and serial 2-fold dilutions of either pristane or mineral oil in PBS/BSA or in medium alone. Cell death (necrosis) was determined by flow cytometry with 7-aminoactinomycin D (7-AAD).
Mass spectrometry. Lung and bone marrow tissue was collected 1 week after pristane treatment and frozen in liquid nitrogen. Metabolites were extracted from 15-30 mg of tissue, which was homogenized with a mortar and pestle under liquid nitrogen. Precooled 80% methanol (0.7 ml) and chloroform (0.7 ml) were added, and the mixture was kept on ice and vortexed every 5 minutes for 30 minutes. Ice-cold double-distilled H 2 O (0.5 ml) was added to ensure separation of the aqueous and organic layers. The tube was centrifuged at 3,200g for 10 minutes at 48C. The organic layers extracted from pristane-treated and untreated mice were diluted in methanol for determining pristane level using a Thermo Scientific LTQ-Orbitrap-XL mass spectrometer. Mass spectra were analyzed using Sciex OS software.
Flow cytometry. Peritoneal exudate and bone marrow cells were surface stained with the following antibodies: Pacific Blue (PB)-conjugated anti-CD11b, allophycocyanin (APC)-Cy7-conjugated anti-Ly-6G or phycoerythrin (PE)-conjugated antiLy-6G (both clone RB6-8C5), and PE-conjugated IL-10 receptor (IL-10R) (all from BioLegend). In some cases, the cells were fixed, permeabilized with Perm/Fix buffer (eBioscience), and stained intracellularly with APC-conjugated anti-tumor necrosis factor (anti-TNF) (BioLegend). In some experiments, the cells were fixed with Cytofix/Perm buffer (BD Biosciences), permeabilized with PhosFlow Permeabilization buffer (BD Biosciences), and stained with PE-conjugated anti-phospho-STAT-3 antibodies (BD Biosciences). Flow cytometry was performed using an LSRII flow cytometer (Becton Dickinson). At least 5 3 10 5 events were collected per sample. Data were analyzed using FlowJo software (Tree Star).
In vivo depletion of neutrophils and macrophages. Neutrophils were depleted by treating with anti-Ly-6G monoclonal antibody IA8 (BioXcell) (250 mg IV per mouse 1 day before and 7 days after pristane treatment) (12) . Mice were euthanized at 14 days for pathologic analysis of DAH. Depletion of neutrophils in the bone marrow, peripheral blood, and peritoneum was ascertained by flow cytometry (PE-conjugated anti-Ly-6G plus PB-conjugated anti-CD11b). Neutrophil depletion in the lung was evaluated by H&E staining and elastase immunohistochemistry.
Macrophages were depleted using clodronate liposomes (CloLip; www.ClodronateLiposomes.com) (13) at 50 ml IP per mouse 1 day before and 7 days after pristane treatment (14) .
Mice were euthanized at 14 days for pathologic evaluation of DAH. Depletion of peritoneal monocytes and macrophages was ascertained by flow cytometry (fluorescein isothiocyanate-conjugated anti-Ly-6C [BioLegend] plus PB-conjugated anti-CD11b).
Depletion in lung was evaluated by H&E staining and immunohistochemistry using horseradish peroxidase (HRP)-conjugated anti-F4/80 (clone BM8; Caltag Medsystems), HRP-conjugated anti-CD11b (clone 5C6; AbD Serotec), or HRP-conjugated anti- 2/2 mice (n 5 12), and B6 CD18 2/2 mice (n 5 4) were treated with pristane, and lungs were examined for DAH 14 days later. Some WT mice were treated with cobra venom factor (CVF) to deplete complement 1 day before pristane treatment (X1; n 5 6) or 1 day before and 7 days after pristane treatment (X2; n 5 10). Left, Gross lung pathology. Right, Prevalence of DAH. *** 5 P , 0.001 versus WT mice not treated with CVF, by Fisher's exact test. C, Hematoxylin and eosin staining of lung tissue from a systemic lupus erythematosus (SLE) patient with DAH (top left) and a WT mouse with pristaneinduced DAH (top right and bottom left) is shown. Lungs show bland hemorrhage (H), neutrophil-predominant small vessel vasculitis (V), and hemosiderin-laden macrophages (MU; arrows). These pathologic changes were absent in lungs from pristane-treated C3 2/2 mice (bottom right). Murine lung was examined 14 days after pristane treatment. Bars 5 20 mm (bottom left); 100 mm (bottom right).
1282
ZHUANG ET AL CD11c (clone N418; Abcam) followed by staining with the immunoperoxidase substrate 3,3 0 -diaminobenzidine. Depletion of F4/801 cells was quantified in a blinded manner by a pathologist (L-JY). Macrophage (F4/80) staining of the perivascular and alveolar regions of lungs from untreated mice (n 5 7) and mice treated with pristane plus clodronate liposomes (n 5 8) was graded as strongly positive (21), weakly positive (11), or absent (01).
Statistical analysis. Data are representative of at least 2 independent experiments and are presented as the mean 6 SD. For normally distributed data, comparisons were performed using Student's unpaired 2-tailed t-test (GraphPad Prism software, version 5). Non-normally distributed data were compared by Mann-Whitney U test. Frequency data were analyzed by Fisher's exact test. Correlations were analyzed using Spearman's rank correlation coefficient. P values less than 0.05 were considered significant.
RESULTS
Requirement of IgM, C3, and CD18 for DAH. B6 mice develop severe DAH 2-4 weeks after IP pristane injection (5), while B cell-deficient (mMT) mice are resistant (7). We investigated whether this was due to the absence of immunoglobulin or to another B cell function. Approximately 60-70% of pristane-treated wild-type (WT) B6 mice developed DAH, which was seen by gross examination of lung tissue ( Figures 1A  and B ). In contrast, mMT mice did not develop DAH, while disease could be restored by IV injection of 200 mg per mouse (but not 50 mg per mouse) of normal human IgM (P , 0.001 by Fisher's exact test) ( Figure  1A ). Infusion of 200 mg per mouse of normal mouse IgG did not restore the ability of pristane to induce disease ( Figure 1A ). In contrast, mMT mice receiving 100 ml of normal mouse serum IV prior to pristane developed DAH (data not shown).
DAH was also absent in C3 2/2 and CD18 2/2 mice ( Figure 1B ). Pretreatment of WT mice with CVF 1 day before and 7 days after pristane treatment prevented DAH, while 69% of untreated mice developed DAH (P , 0.001 by Fisher's exact test) ( Figure 1B) . A single CVF treatment (1 day before pristane) was partially protective. H&E-stained lung tissue from WT mice showed hemorrhage, pulmonary vasculitis with neutrophilic and mononuclear cell infiltrates surrounding the capillaries and small arteries, and hemosiderin-laden macrophages within the alveoli ( Figure 1C ). These changes were absent in C3
2/2 mice. Nearly identical changes were seen in H&E-stained tissue from a lupus patient with DAH (Figure 1C) . Thus, DAH in pristane-induced lupus closely resembles human lupus-associated DAH pathologically and is mediated by IgM, C3, and CD18, a component of the C3b receptors CR3 and CR4.
Migration of pristane to lung after IP injection. We investigated the mechanism(s) responsible for DAH. Although pristane is injected IP, we hypothesized that it may gain access to the lungs. To examine that possibility, lung tissue was extracted 7 days after pristane treatment and analyzed by mass spectrometry (Figures 2A and B) . A pristane standard yielded the characteristic fragmentation pattern of molecular ion peaks (M), with mass/charge ratios of 268 (M), 267 (M 2 1), 269 (M 1 1), and 270 (M 1 2) (Figure 2A ). The 4 characteristic peaks were seen in lung tissue of IP pristane-treated WT mice, but not untreated WT mice ( Figure 2B ). Pristane was also detected in the lung from treated C3 2/2 mice, but not untreated C3 2/2 mice (Figure 2B) , indicating that C3 is not necessary for migration of pristane from peritoneum to lung. To confirm the presence of pristane in the lung, cryosections of lung tissue from pristane-treated mice were stained with oil red O, revealing numerous oil red O-positive droplets within the alveolar walls ( Figure 2C ). Oil red O-stained material was absent in lung from untreated mice, consistent with the mass spectrometry data. Peritoneal pristane injection also causes bone marrow inflammation (15) , and pristane was detected by mass spectrometry in bone marrow of pristane-treated mice, but not in bone marrow of untreated mice ( Figure 2D ), which suggests that the oil was widely dispersed following IP injection.
Cell death induction by pristane. Examination of lung tissue by TUNEL assay revealed dead cells in pristane-treated mice but not in untreated controls ( Figure 3A ). Many TUNEL-positive cells were large, vacuolated cells located within the alveoli, reminiscent of alveolar macrophages, but smaller TUNEL-positive cells were also present. Dead cells also accumulate in the bone marrow of pristane-treated mice (15) , which suggests that pristane might be cytotoxic. That possibility was examined by incubating mouse BW5147 T cells with pristane or mineral oil (the latter of which causes minimal alveolar hemorrhage [not shown]). BW5147 cells exposed in vitro to pristane, but not to mineral oil, exhibited dose-dependent induction of cell death (i.e., were 7-AAD1) ( Figure 3B ). In contrast, RAW 264.7 macrophages were resistant to the cytotoxic effects of pristane, with no significant 7-AAD staining ( Figure 3C ). Taken together, the data indicate that pristane migrates from the peritoneum to the lungs and other tissues, where it may cause death of certain cell types. Opsonization of these dead cells by IgM and C3 may promote pulmonary inflammation, as also seen in the peritoneum (8) .
Role of macrophages in DAH. Normal lung contains several subsets of macrophages and dendritic cells, but bone marrow-derived monocytes and neutrophils are recruited during inflammation (16, 17) . We examined the role of monocyte/macrophages versus that of neutrophils in DAH by selectively depleting these subsets in WT mice. Neutrophil depletion with antiLy-6G antibodies greatly decreased total peritoneal neutrophils and peritoneal neutrophils containing intracellular TNF, but had little effect on bone marrow neutrophils ( Figure 4A ). In the lung, neutrophils were decreased in H&E-and neutrophil elastase-stained sections ( Figure 4B ). Perivascular neutrophilic infiltrates were markedly reduced ( Figure 4B ). However, numerous perivascular F4/801 macrophages remained after anti-Ly-6G treatment ( Figure 4C ), despite depletion of elastase-positive cells ( Figure  4D ).
In contrast, treatment with clodronate liposomes, which depletes monocyte/macrophages (13) , abolished the perivascular infiltrates in pristane-treated mice ( Figure 4E ). 
PATHOGENESIS OF ALVEOLAR HEMORRHAGE 1285
The frequency of DAH was greatly reduced in mice treated with clodronate liposomes (P , 0.001 by Fisher's exact test), but was unaffected by neutrophil depletion ( Figure 4F ).
Like DAH, the localized Shwartzman reaction in skin is associated with thrombohemorrhagic vasculitis mediated by C3b-CR3 interactions (18) . CR3-mediated neutrophil activation results in vessel damage due to neutrophil elastase production. However, elastasedeficient mice were fully susceptible to pristane-induced DAH ( Figure 4F ). They also developed pulmonary vasculitis (not shown). Type I IFN and TNF production also remained intact in elastase-deficient mice (not shown). Thus, although it superficially resembles the localized Shwartzman reaction, DAH is not mediated by neutrophils and instead appears to be mediated by macrophages.
Depletion of alveolar and perivascular macrophages by clodronate liposomes. Perivascular inflammatory cell infiltrates in lungs from pristanetreated mice contained small F4/80 high cells ( Figures 4C  and 5A, top) . Perivascular CD11b1 cells were also present ( Figure 5A, top) , but it could not be determined whether CD11b staining was associated with F4/80 
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The alveolar septa appeared thickened in clodronate liposome-treated mice, despite the absence of alveolar hemorrhage. There was no alveolar hemorrhage in 6 of 8 clodronate liposome-treated mice, while 2 mice exhibited mild alveolar hemorrhage (P , 0.001 by Fisher's exact test) ( Figure 4F ). The severity of alveolar hemorrhage and vasculitis seemed to be related to the extent of F4/801 macrophage depletion. Hemorrhage was absent in mice exhibiting complete depletion of the perivascular and alveolar F4/801 cells, while the 2 mice with mild DAH had only partial depletion of F4/801 cells, which suggests that clodronate liposome treatment was incomplete. Clodronate liposome treatment also depletes Ly-6C high CD11b1 inflammatory macrophages from the peritoneum (14) . Lung from pristane-treated CD18 2/2 mice showed no evidence of alveolar hemorrhage or F4/801 macrophages, but in contrast to clodronate liposome-treated WT mice, alveolar architecture was normal ( Figure 5C ). Mild thickening of the alveolar septa in mice treated with pristane plus clodronate liposomes compared with untreated B6 controls was also apparent on H&E staining and F4/80 immunohistochemistry analysis ( Figure 5D ).
Mechanism of lung inflammation. Lung interstitial macrophages and epithelial cells are antiinflammatory and secrete 21) . Although alveolar macrophages are normally antiinflammatory, when activated via TLRs, IL-10R signal transduction is inhibited and they become proinflammatory (21, 22) . Thus, IL-10 is a crucial regulator of lung inflammation. Expression of CD11b suggested that alveolar macrophages from pristane-treated mice are activated ( Figure 5A ). Accordingly, we examined the effect of IL-10 on DAH. IL-10 2/2 mice had significantly increased mortality from DAH ( Figure 6A ). Pristane-treated B6 mice had mortality of ;40% at 1 month, but little additional mortality thereafter. There was no DAH ( Figure  1B) or mortality up to 24 weeks after pristane treatment of C3 2/2 mice ( Figure 6A ). In contrast, mortality from DAH was nearly 75% in IL-10 2/2 mice (P , 0.005 by Mantel-Cox test) ( Figure 6A) .
TLR-activated genes are targeted by IL-10 (23), and pristane induces proinflammatory cytokine production via TLR-7 (24). Unexpectedly, MyD88 2/2 and TRIF
2/2
mice developed DAH at a frequency similar to that of WT mice ( Figure 6B ). Pristane also induced DAH in TNF 2/2 and IFNAR 2/2 mice. Consistent with our previous observations that proinflammatory cytokine production in pristane-treated mice is TLR-7/MyD88 dependent (15, 24) , neutrophils from pristane-treated MyD88 2/2 mice did not produce TNF, while neutrophils from TRIF 2/2 and WT mice exhibited similar TNF production ( Figure 6C ).
As IL-10 inhibits IL-1 production, we tested caspase 1-deficient mice, but we found no protection against DAH ( Figure 6B ). Although NO production can damage the alveolar wall (25), NOS2
2/2 mice were susceptible to pristane-induced DAH ( Figure 6B) .
To further examine the role of IL-10, we stained bone marrow myeloid cells from untreated and 1-month pristane-treated B6 mice with anti-IL-10R antibodies. As expected, CD11b1Ly-6G2 monocytes expressed IL-10R, while neutrophils (CD11b1Ly-6G1) were mostly negative ( Figure 6D ). IL-10R staining of bone marrow monocytes was decreased in pristane-treated mice compared with mineral oil-treated mice ( Figure 6D ).
Alveolar macrophages (CD11b1F4/801CD11c1 Siglec F positive CD2051) were present in BAL fluid from untreated mice ( Figure 6E ). As reported (22), they expressed IL-10R. IL-10R was also expressed by alveolar macrophages collected by BAL from mineral oil-and pristane-treated mice, with a trend toward lower expression in pristane-treated mice (data not shown). Alveolar macrophages collected by BAL from pristanetreated and mineral oil-treated mice were incubated for 15 minutes with IL-10, followed by staining with antibodies against CD11b (expressed by activated alveolar macrophages) and anti-phospho-STAT-3 antibodies. As shown in Figure 6F , STAT-3 activation was higher in alveolar macrophages from mineral oil-treated mice, which suggests that pristane treatment decreases the responsiveness of alveolar macrophages to IL-10.
DISCUSSION
Lupus-associated DAH has a mortality of .50% (2,3). Either bland hemorrhage or focal pulmonary capillaritis may be present in DAH due to lupus or vasculitis. Capillaritis occurs in 88% of patients, most commonly in granulomatosis with polyangiitis (Wegener's) (GPA), microscopic polyangiitis (MPA), and SLE (26) , and it is often associated with fibrin thrombi occluding the intraalveolar capillaries and fibrinoid necrosis of the small blood vessels. It may be accompanied by inflammation of larger vessels and IgG/C3 deposition in the alveolar walls. In contrast to leukocytoclastic vasculitis, erythrocytes extravasate into the alveolar spaces (and not the interstitium) in DAH (26) .
B6 mice with pristane-induced lupus develop hemorrhage and pulmonary capillaritis that is morphologically similar to human SLE-associated DAH (5-7) ( Figure 1C ). DAH required CD18 (a component of CR3 and CR4) and opsonization of dead cells by natural IgM and the early classical pathway of complement. Unexpectedly, macrophages, but not neutrophils, were required for disease. Consistent with the importance of macrophage activation, disease was exacerbated in IL-10 2/2 mice. However, in contrast to the TLR-7 dependency of proinflammatory cytokine production (15, 24) , DAH was independent of MyD88, TRIF, TNF, and NOS2. Although both type I IFN (27) and inflammasomes (28) are involved in pristane-induced lupus, IFNAR 2/2 and caspase 1-deficient mice (which are also caspase 11-deficient [29] ) were not protected. Thus, DAH was independent of IFN and the canonical and noncanonical inflammasome pathways.
Opsonization of dead cells may initiate lung injury. Defective clearance of dead cells by resident lung phagocytes contributes to inflammation in acute lung injury, asthma, cystic fibrosis, and chronic obstructive pulmonary disease (30) . Human SLE and pristane-induced lupus both are associated with impaired apoptotic cell clearance, and mouse models suggest that this promotes lupus (31) . Monocyte-derived macrophages from SLE patients are poorly phagocytic (32) . Patients and lupus mice both exhibit increased numbers of uncleared apoptotic cells in tissues (15, 33) . Accumulation of dead cells in the lungs of pristane-treated mice may be partly due to the cytotoxicity of pristane. Consistent with an earlier report (34) , pristane caused dose-dependent T cell death, but RAW 264.7 macrophages were resistant. Widespread dissemination of pristane after peritoneal injection may promote apoptosis and defective removal of dead cells in the lung (Han S: unpublished observations), as suggested by the TUNEL-positive cells in lungs of pristane-treated mice ( Figure 3A) and consistent with the presence of dead cells in the lungs of SLE patients with DAH (data not shown).
Interestingly, TUNEL staining suggested that large cells whose appearance was consistent with that of alveolar macrophages were undergoing cell death. That possibility is supported by evidence that the recovery of alveolar macrophages by BAL was decreased in pristane-treated mice compared with mineral oil-treated mice (not shown). Thus, there may be differences in the susceptibility of various macrophage subsets to the induction of cell death by pristane. Although resident alveolar macrophages are generally more resistant to apoptosis than are macrophages recruited to the lung (35) , engagement of the scavenger receptor macrophage receptor with collagenous structure (MARCO) sensitizes them to undergo apoptosis following uptake of silica (36) . As MARCO is involved in the uptake of apoptotic cells in pristane-treated mice (Han S, et al: submitted for publication), the uptake of dead cells may sensitize alveolar macrophages to apoptosis. Further studies will be necessary to determine the cause of the differential susceptibility of alveolar macrophages and RAW 264.7 cells to pristane-induced apoptosis.
Our data suggest that DAH is mediated by opsonin-dependent uptake of dead cells, as natural IgM, C3, and CD18 are required. Induction of the IFN signature by pristane also requires IgM and C3 due to opsonization of dead cells and phagocytosis via CR3 and/or CR4 (8) . Since CD11b 2/2 mice are protected against pristane-induced DAH (37), CR3 is likely to play an important role in the pathogenesis of lung inflammation. Our data suggest that the importance of CD11b and CD18 in lung inflammation lies in the role of CR3 as a phagocytic receptor rather than as a mediator of cell adhesion and migration. An additional role for CR4 (CD11c/CD18) cannot be excluded.
Alveolar hemorrhage is thought to emanate from neutrophilic inflammation of capillaries (capillaritis) (38) , and neutrophils are also critical to the pathogenesis of acute lung injury induced by endotoxin, shock, and ischemiareperfusion injury (39) . The lungs of pristane-treated mice exhibited neutrophilic infiltration, but F4/801 macrophages and other myeloid cells were also present. Although the pulmonary vasculitis superficially resembled a localized Shwartzman reaction (neutrophilic infiltration, erythrocyte extravasation, and dependence on C3 and neutrophil CR3) (18), neutrophil depletion had little effect on DAH. It was also unaffected by the absence of neutrophil elastase, a key mediator of the Schwartzman reaction (18) . DAH was greatly attenuated by treatment with clodronate liposomes, suggesting that cells of the monocyte/macrophage lineage, rather than neutrophils, are central to the pathogenesis of lung hemorrhage. Although acute lung injury can be associated with alveolar hemorrhage, neutrophils, IL-1, and TNF are key mediators of inflammation (39) , which suggests that pristane-induced DAH differs from acute lung injury.
At mice, we cannot determine which subset causes lung injury.
IL-10 down-regulates proinflammatory cytokine production by macrophages at multiple (transcriptional and posttranscriptional) levels (41) . Its constitutive production by lung interstitial macrophages and epithelial cells helps maintain the antiinflammatory phenotype of alveolar macrophages, and BAL fluid from untreated mice contains IL-10 thought to be derived mainly from lung epithelial cells (20, 42) . DAH was more severe in IL-10 2/2 mice than in controls, which suggests that IL-10 protects against pristane-induced lung injury by interacting with IL-10R on alveolar macrophages or bone marrow-derived cells.
During inflammation, bone marrow-derived macrophages are recruited to the alveoli and differentiate into proinflammatory (M1-type) macrophages (25) . IL-10R expression in untreated bone marrow was restricted to CD11b1Ly-6G2 cells of the monocyte lineage. After pristane injection, these cells are recruited to the inflamed peritoneum via CCL2-CCR2 (43) . In the absence of type I IFN, they develop into Ly-6C l 8 w macrophages, while maturation is inhibited by IFN. Decreased IL-10R expression on bone marrow monocytes from pristane-treated mice compared with controls ( Figure 6 ) suggests that monocytes recruited to the inflamed lung in pristane-treated mice may be poorly responsive to the antiinflammatory effects of locally produced IL-10, consistent with the decreased STAT-3 phosphorylation in BAL cells from pristanetreated mice compared with those from mineral oiltreated mice. It will be of interest to see if the higher IL-10R expression by bone marrow monocytes from mineral oil-treated mice promotes differentiation into antiinflammatory (M2-type) macrophages, while low IL-10R expression in pristane-treated mice results in M1-type polarization.
The inflammatory pathway(s) activated when IgM/ C3-opsonized dead cells engage CR3/CR4 on macrophages remain to be determined. IL-10 down-regulates TLRstimulated transcription of proinflammatory cytokines by inducing ubiquitination and degradation of MyD88-dependent signaling molecules, such as TNF receptorassociated factor 6 and IL-1R-associated kinase 4 (44) . In view of the importance of TLR-7 and MyD88 in pristaneinduced proinflammatory cytokine production, it was surprising that DAH develops in TLR-7 2/2 (7) and MyD88 2/2 mice. DAH also developed in pristane-treated TRIF 2/2 mice. Thus, the pathogenesis of DAH may not involve TLR signaling, although it will be necessary to examine the susceptibility of MyD88/TRIF-double-deficient mice to exclude the possibility that TRIF and MyD88 can compensate for one another. Pristane causes sterile inflammation, which is a result of innate immune recognition of damageassociated molecular patterns released from dead cells (45) . Sterile inflammation is mediated by both neutrophils and monocytes. Neutrophil-mediated inflammation requires MyD88, IL-1a, and IL-1R, but not TRIF or TLRs, whereas the monocytic response is MyD88/IL-1R independent (46, 47) . The susceptibility of MyD88 2/2 mice and caspase 1/ caspase 11-deficient mice ( Figure 6B ) further supports the idea that macrophages rather than neutrophils mediate DAH. Although NOS2 has been implicated in bleomycininduced lung injury (48), it was not involved in pristaneinduced DAH. Further studies are needed to define the inflammatory pathway(s) downstream of CR3/CR4 that lead to DAH.
DAH is an unusual manifestation of SLE with high mortality and unclear etiology (3, 4) . Although a variety of therapeutic interventions are used, their efficacy is unclear (3,4) . The pathologic changes in pristane-induced DAH, especially the presence of capillaritis, closely resemble those in patients with DAH. Like DAH in SLE patients, murine DAH is not associated with ANCAs, and hemosiderin-laden macrophages are present (6) ( Figure 1C ). Moreover, dead cells accumulate in lung tissue from humans with DAH (Zhuang H: unpublished observations) as well as in lung tissue from animals with pristane-induced DAH. In contrast to chemical pneumonitis and ANCA-positive vasculitis syndromes, such as MPA and GPA, SLE-associated DAH is thought to be mediated by immune complexes with granular deposits of immunoglobulin, C3, and DNA in the alveolar capillary walls (49) . The requirement for immunoglobulin and C3 in pristane-induced DAH is consistent with the role of immune complexes in this animal model, further underscoring the similarity between DAH in SLE patients and in mice.
Interestingly, hemoptysis and lung fibrosis have been seen in humans with inhalation, aspiration, or injection of mineral and other oils (50, 51) . Although humans are generally not exposed to pristane, the strong phenotypic and pathologic similarities (15, 52) suggest that pristane exposure may activate inflammatory pathways similar to those in SLE patients. Respiratory infections, seen in 40-60% of patients with SLEassociated DAH (3, 4, 53) , represent one mechanism that could drive the accumulation of apoptotic cells in the lungs, promoting DAH. It will be of interest to investigate the role of these infections in the pathogenesis of DAH in humans.
The response of pristane-induced DAH to CVF ( Figure 1B ) raises the possibility that complement depletion/inhibition may be a viable strategy for treating DAH in human SLE. Although CVF is too immunogenic for human use, "humanized" CVF is undergoing clinical testing (54) , and compstatin, a 13-residue cyclic peptide that inhibits activation of the classical and alternative complement pathways, is in clinical trials for macular degeneration (55) . Complement inhibition also blocks pulmonary fibrosis (56), a long-term complication of DAH (57) . As pulmonary fibrosis is also seen in lupus patients without prior overt episodes of DAH (1), it will be of interest to examine whether clinically silent DAH with alveolar microhemorrhage can cause pulmonary fibrosis. Finally, in view of the severity of disease in IL-10-deficient mice, it may be of interest to evaluate recombinant IL-10 as a potential therapy.
